MAP4K4 Enzyme a Potential Therapeutic Target in ALS, Study Suggests

Suppressing an enzyme known as MAP4K4 extended the survival of motor neurons collected from mice and patients with amyotrophic lateral sclerosis (ALS), and decreased the accumulation of toxic proteins associated with the disease, a study reports. These findings from the study, titled “MAP4K4 Activation Mediates Motor…

I have ALS. That awareness has prompted a series of rapid-fire questions. While many of us would describe existence as being comprised of multiple chapters, I now have two distinctly different lives. Prior to ALS, I had led an unremarkable life largely characterized by good fortune. Some of…

A “new voice” for people who cannot verbally communicate, such as those living with amyotrophic lateral sclerosis (ALS) or recovering from stroke, is a step closer to becoming reality. Researchers from the Zuckerman Institute at Columbia University have developed a computer algorithm that can recognize a person’s thoughts as…

Do you speak with an “ALS accent”? I know I do. Fortunately, my family and close friends have learned to translate my slow, slurred words into meaningful conversation. However, to the Alexa device that lives in our back bedroom and the Echo Show that sits near me, my ALS…

An immune response triggered by T-cells contributed to the elimination of motor neurons in a mouse model of amyotrophic lateral sclerosis (ALS), a study shows. The study, “Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons,” was published in PNAS. ALS is…

SIRION Biotech and Denali Therapeutics have signed a new licensing agreement to develop a new generation of adeno-associated virus (AAV) vectors, harmless viruses used as vehicles to deliver gene therapies, to allow therapies to reach into the central nervous system (CNS) of people  with amyotrophic lateral sclerosis (ALS). The…

An upcoming webinar will focus on the novel approach to clinical trial design in the Modifying Immune Response and Outcomes in ALS (MIROCALS) trial, which aims to break the current impasse in therapy development for amyotrophic lateral sclerosis (ALS). During the webinar, P. Nigel Leigh, a motor neuron disease…

Tau and FUS proteins may contribute to a cellular process common to both amyotrophic lateral sclerosis (ALS) and dementia, a rare case suggests. The case was reported in a study, “Combined FUS+ Basophilic Inclusion Body Disease and Atypical Tauopathy Presenting with an ALS/MND‐plus Phenotype,” published…

“It takes a village to raise a child.” That African proverb is a testimony to the primary, secondary, and even cameo influences that factor into the sustaining, nurturing, and ennobling of a human from infancy until independent adulthood. When done properly, a gradual lessening…

MediciNova’s  investigational therapy ibudilast (MN-166) combined with Rilutek (riluzole), for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, has been given final approval — a notice of allowance stating that its request for a patent is being considered by the U.S. Patent and Trademark Office. Receiving a notice of allowance is the final…